Efficacy, Safety of Rimegepant When Used Both as Preventively and As-Need: Richard B. Lipton, MD
July 10th 2022The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]
Understanding the Impact of MiCOAS Qualitative Study: Richard B. Lipton, MD
July 8th 2022The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]